The science of recruiting minority populations to screening trials

Clinical Trials

Volumn 1, Issue 4, 2004, Pages 341-342

  Ford, Jean g ^a   Howerton, Mollie ^b  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFRICAN AMERICAN; CLINICAL TRIAL; EDITORIAL; HUMAN; METHODOLOGY; MINORITY GROUP; PATIENT SELECTION;

AFRICAN AMERICANS; CLINICAL TRIALS; HUMANS; MINORITY GROUPS; PATIENT SELECTION; RESEARCH DESIGN;

EID: 32944476728     PISSN: 17407745     EISSN: None     Source Type: Journal    
DOI: 10.1191/1740774504cn034ed     Document Type: Editorial

References (16)

1. ACS. Cancer facts and figures for African Americans: 2003-2004. Atlanta: American Cancer Society, 2003.
2. Adler NE. A consideration of multiple pathways from socioeconomic status to health. In Auerbach J.A., Krimgold B.K. eds. Income, socioeconomic status, and health: Exploring the relationship. Washington, DC: National Policy Association, 2001, 56-66.
3. Ward E., Jemal A., Cokkinides V. et al. Cancer disparities by race/ethnicity and socioeconomic status. CA Cancer J Clin 2004; 54: 78-93.
4. Sateren W.B., Trimble E.L., Abrams J. et al. How sociodemographics, presence of oncology specialists, and hospital cancer programs affect accrual to cancer treatment trials. J Clin Oncol 2002. 20: 2109-2117.
5. Altman D.G. Statistics and ethics in medical research: III How large a sample? Br Med J 1980; 281 1336-1338.
6. Cooper R.S., Kaufman J.S., Ward R. Race and genomics. N Engl J Med 2003; 348: 1166-1170.
7. Corbie-Smith G., Miller W.C., Ransohoff D.F. Interpretations of “appropriate” minority inclusion in clinical research. Am J Med 2004; 116: 249-252.
8. Lynch T.J., Bell D.W., Sordella R. et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129-2139.
9. Moser M., Lunn J. Responses to captopril and hydrochlorothiazide in black patients with hypertension. Clin Pharmacol Ther 1982; 32: 307-312.
10. Emanuel E., Wendler D., Grady C. What makes clinical research ethical? JAMA 2000; 283: 2701-2711.
11. Ford M.E., Havstad S.L., Davis S. Randomized trial outcomes for older African American men recruited to the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Clin Trials 2004; 1: 343-351.
12. Cross C.K., Harris J., Recht A. Race, socioeconomic status, and breast carcinoma in the U.S: what have we learned from clinical studies. Cancer 2002; 95: 1988-1999.
13. Andes N., Davis J.E. Linking public health data using geographic information system techniques: Alaskan community characteristics and infant mortality. Stat Med 1995; 14: 481-490.
14. Prescott R.J., Counsell C.E., Gillespie W.J. et al. Factors that limit the quality, number and progress of randomised controlled trials. Health Technol Assess 1999; 3: 1-143.
15. Elster A., Jarosik J., VanGeest J., Fleming M. Racial and ethnic disparities in health care for adolescents: a systematic review of the literature. Arch Pediatr Adolesc Med 2003; 157: 867-874.
16. el-Sadr W., Capps L. The challenge of minority recruitment in clinical trials for AIDS. JAMA 1992; 267: 954-957.